Business context and reporting period
This is Ikena Oncology, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2023. The request identifies Imagenebio, Inc.; that does not match the registrant named in the filing. Ikena develops targeted oncology therapies and has no approved products or product-sale revenue. Its programs include IK-930, IK-595 and Bristol Myers Squibb-partnered IK-175. In August 2023, Ikena acquired Pionyr Therapeutics.
Financial performance and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Collaboration revenue | $1.2 million | $6.4 million | $8.5 million | $10.2 million |
| Research and development expense | $14.7 million | $18.9 million | $45.4 million | $48.7 million |
| General and administrative expense | $6.0 million | $5.4 million | $16.6 million | $17.3 million |
| Net loss | $17.3 million | $17.3 million | $48.7 million | $54.7 million |
| Net loss per share | $0.40 | $0.48 | $1.23 | $1.51 |
At September 30, 2023, cash and cash equivalents were $121.3 million and marketable securities were $75.7 million, totaling $196.9 million. Current assets were $200.6 million and current liabilities $19.3 million. Accumulated deficit was $262.9 million. The filing reports no borrowings or debt balance. No meaningful operating margin is presented; the company remains loss-making and has no product sales.
For the first nine months, operating cash use was $57.9 million, compared with $56.5 million in 2022. Investing activities provided $43.8 million, primarily from marketable-security maturities and sales, while financing provided $75.9 million, mainly from the Pionyr transaction and a stock offering. Capital expenditures were $0.2 million. Management expects available cash, cash equivalents and marketable securities to fund operating and capital requirements into 2026, subject to assumptions and risks.
Material changes versus the prior comparable period
- Third-quarter collaboration revenue fell 81% year over year, mainly because IK-412 manufacturing activities had been substantially completed in 2022. Nine-month revenue fell 16%.
- Research and development expense declined 22% in Q3 and 7% for the nine-month period, reflecting lower IK-175 clinical costs and reduced discovery/early-stage spending, partly offset by Pionyr wind-down costs. Nine-month G&A declined 4%, although Q3 G&A rose 11%, primarily due to legal expense.
- Nine-month net loss improved by $6.0 million, partly reflecting higher investment income. Q3 net loss was essentially unchanged.
- The May 2023 underwritten offering raised approximately $37.4 million net. The Pionyr acquisition added approximately $43 million of net cash at closing, alongside equity issuance and contingent value rights.
Outlook, commentary, risks and unusual items
- Management expects significant expenses and operating losses to continue and says additional financing may be needed. There is no committed external funding source; future equity financing could dilute shareholders.
- Management anticipated IK-595 Phase I clinical program activities to begin in Q4 2023. Additional IK-930 clinical data were expected in the second half of 2024, and an IK-930/osimertinib collaboration cohort was planned to begin in 2024.
- Bristol Myers Squibb’s option period for IK-175 and IK-412 runs through January 2024. The filing says Ikena stopped the IK-175 head-and-neck study before enrolling participants to focus resources on the partnership data package. IK-412 development remains paused apart from previously committed manufacturing work.
- The Series A preferred shares issued for Pionyr converted into common shares effective October 16, 2023, after stockholder approval on October 11. This post-quarter conversion is a material capital-structure development.
- Pionyr holders received contingent value rights entitling them to 50% of net proceeds, excluding royalties, from potential monetization of Pionyr legacy programs within two years. The contingent amount was not reasonably estimable at quarter-end.
- Key risks include clinical and regulatory uncertainty, dependence on third-party manufacturers and CROs, single-source API suppliers, the need for future capital, collaboration-partner decisions, and the challenges of integrating Pionyr. Management reported disclosure controls effective at the reasonable-assurance level, but excluded Pionyr’s internal controls from its evaluation while integration proceeds.
Important facts for investors to verify
- Confirm the intended company: the supplied filing is for Ikena Oncology, not Imagenebio.
- Check subsequent disclosures on IK-595 trial initiation, IK-930 clinical data, and Bristol Myers Squibb’s options before and after January 2024.
- Assess the stated runway into 2026 against actual cash burn, development plans, and financing needs.
- Review the common-share impact of the Pionyr preferred-stock conversion and any further dilution or contingent value right payments.
- Verify progress in Pionyr integration, including the vacant San Francisco lease, and any changes to program priorities or costs.